Why Arrowhead Shot Sky-High, While Ionis Toppled
Arrowhead Pharmaceuticals shares surged following positive Phase 3 trial results for its lipid-lowering drug, impacting competitor Ionis.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Arrowhead's drug, plozasiran (also referred to as redemplo), has demonstrated a reduction in triglycerides and pancreatitis events in Phase 3 trials for severe hypertriglyceridemia (sHTG). Coverage from BioPharm International, Fierce Pharma, and Managed Healthcare Executive emphasizes the drug's ability to cut pancreatitis risk and lower triglycerides.
Seeking Alpha and Investor's Business Daily report a divergence in market performance, with Arrowhead's stock rising while Ionis's value dropped. Future developments center on the implications of these late-stage trial wins for the competitive landscape of lipid-lowering treatments.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What drug is responsible for Arrowhead's stock increase?
The drug is plozasiran, also identified as redemplo.
What were the specific results of the Phase 3 trials?
The trials for severe hypertriglyceridemia showed that the drug reduces triglycerides and pancreatitis events.
How did Ionis react to the news?
According to Seeking Alpha and Investor's Business Daily, Ionis's stock dropped following Arrowhead's late-stage trial win.
Coverage (6)
- Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight AlphaStreet · 4h ago
- Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia Managed Healthcare Executive · 5h ago
- Arrowhead's Plozasiran Reduces Triglycerides, Pancreatitis Events in Phase 3 sHTG Trials BioPharm International · 5h ago
- Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug Seeking Alpha · 5h ago
- Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data Fierce Pharma · 5h ago
- Why Arrowhead Shot Sky-High, While Ionis Toppled Investor's Business Daily · 5h ago
Topics
Related trends
Why AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jump
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
Compass says depression drug has long-lasting benefits
Compass Pathways reports long-lasting benefits from its psilocybin depression treatment following a second Phase 3 trial.